Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation

Chih Wei Shih, Chung May Yang, Muh Shy Chen, Tsung Jen Wang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: To report the effect of intravitreal injection of bevacizumab and gas for the treatment of diabetic premacular hemorrhage with active fibrovascular proliferation. Methods: Six eyes of six consecutive patients with acute diabetic premacular hemorrhage and active fibrovascular proliferation received intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting. All six cases had panretinal photocoagulation prior to the procedure. After treatment, patients maintained a prone position for 3 days and were followed for an average of 8 months (range, 4-13 months). Results: All six eyes had complete reabsorption of the hemorrhage and reduction of fibrovascular proliferation. Transient vitreous opacification from breakthrough of the blood were observed in all eyes. An average of 3.8 weeks (range, 1-6 weeks) was required for the clearing of preretinal hemorrhage. Visual acuity improved in all six eyes. No recurrent bleeding or other adverse events were encountered in all cases. Conclusions: Intravitreal injection of bevacizumab and gas may be an effective method for treating acute diabetic premacular hemorrhage with active fibrovascular proliferation.

Original languageEnglish
Pages (from-to)1547-1551
Number of pages5
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume246
Issue number11
DOIs
Publication statusPublished - 2008

Fingerprint

Intravitreal Injections
Gases
Hemorrhage
Prone Position
Light Coagulation
Visual Acuity
Bevacizumab
Therapeutics

Keywords

  • Bevacizumab
  • Diabetic premacular hemorrhage
  • Intravitreal gas

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation. / Shih, Chih Wei; Yang, Chung May; Chen, Muh Shy; Wang, Tsung Jen.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 246, No. 11, 2008, p. 1547-1551.

Research output: Contribution to journalArticle

@article{4d41f01ece49476eaf608d1f83065deb,
title = "Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation",
abstract = "Background: To report the effect of intravitreal injection of bevacizumab and gas for the treatment of diabetic premacular hemorrhage with active fibrovascular proliferation. Methods: Six eyes of six consecutive patients with acute diabetic premacular hemorrhage and active fibrovascular proliferation received intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting. All six cases had panretinal photocoagulation prior to the procedure. After treatment, patients maintained a prone position for 3 days and were followed for an average of 8 months (range, 4-13 months). Results: All six eyes had complete reabsorption of the hemorrhage and reduction of fibrovascular proliferation. Transient vitreous opacification from breakthrough of the blood were observed in all eyes. An average of 3.8 weeks (range, 1-6 weeks) was required for the clearing of preretinal hemorrhage. Visual acuity improved in all six eyes. No recurrent bleeding or other adverse events were encountered in all cases. Conclusions: Intravitreal injection of bevacizumab and gas may be an effective method for treating acute diabetic premacular hemorrhage with active fibrovascular proliferation.",
keywords = "Bevacizumab, Diabetic premacular hemorrhage, Intravitreal gas",
author = "Shih, {Chih Wei} and Yang, {Chung May} and Chen, {Muh Shy} and Wang, {Tsung Jen}",
year = "2008",
doi = "10.1007/s00417-008-0902-8",
language = "English",
volume = "246",
pages = "1547--1551",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation

AU - Shih, Chih Wei

AU - Yang, Chung May

AU - Chen, Muh Shy

AU - Wang, Tsung Jen

PY - 2008

Y1 - 2008

N2 - Background: To report the effect of intravitreal injection of bevacizumab and gas for the treatment of diabetic premacular hemorrhage with active fibrovascular proliferation. Methods: Six eyes of six consecutive patients with acute diabetic premacular hemorrhage and active fibrovascular proliferation received intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting. All six cases had panretinal photocoagulation prior to the procedure. After treatment, patients maintained a prone position for 3 days and were followed for an average of 8 months (range, 4-13 months). Results: All six eyes had complete reabsorption of the hemorrhage and reduction of fibrovascular proliferation. Transient vitreous opacification from breakthrough of the blood were observed in all eyes. An average of 3.8 weeks (range, 1-6 weeks) was required for the clearing of preretinal hemorrhage. Visual acuity improved in all six eyes. No recurrent bleeding or other adverse events were encountered in all cases. Conclusions: Intravitreal injection of bevacizumab and gas may be an effective method for treating acute diabetic premacular hemorrhage with active fibrovascular proliferation.

AB - Background: To report the effect of intravitreal injection of bevacizumab and gas for the treatment of diabetic premacular hemorrhage with active fibrovascular proliferation. Methods: Six eyes of six consecutive patients with acute diabetic premacular hemorrhage and active fibrovascular proliferation received intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting. All six cases had panretinal photocoagulation prior to the procedure. After treatment, patients maintained a prone position for 3 days and were followed for an average of 8 months (range, 4-13 months). Results: All six eyes had complete reabsorption of the hemorrhage and reduction of fibrovascular proliferation. Transient vitreous opacification from breakthrough of the blood were observed in all eyes. An average of 3.8 weeks (range, 1-6 weeks) was required for the clearing of preretinal hemorrhage. Visual acuity improved in all six eyes. No recurrent bleeding or other adverse events were encountered in all cases. Conclusions: Intravitreal injection of bevacizumab and gas may be an effective method for treating acute diabetic premacular hemorrhage with active fibrovascular proliferation.

KW - Bevacizumab

KW - Diabetic premacular hemorrhage

KW - Intravitreal gas

UR - http://www.scopus.com/inward/record.url?scp=54049155663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049155663&partnerID=8YFLogxK

U2 - 10.1007/s00417-008-0902-8

DO - 10.1007/s00417-008-0902-8

M3 - Article

C2 - 18682973

AN - SCOPUS:54049155663

VL - 246

SP - 1547

EP - 1551

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 11

ER -